What are the benefits and harms of using tricyclic antidepressants (TCAs) for neuropathic pain?
Compared to placebo^ TCAs may provide a 30% reduction in pain for an additional 1 in 4-6 people with neuropathic pain^ with 1 in 5 experiencing an adverse event and 1 in 11 stopping medication because of side effects. Overall^ evidence is limited by inconsistent outcome reporting in small studies of short duration.
Publication Date: 2018-5-7
Last Updated on PCR: 2018-05-08 11:48:19